2Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
4Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases : prospective cohort study[ J]. BMJ,2004,328:983. 被引量：1
5European Association For The Study Of The Liver. EASL Clinical Practice Guidelines:management of chronic hepatitis B [ J ]. J Hep- atol,2009 ,50 :227 - 242. 被引量：1
6Yao GB. Enteeavir is a potent anti-HBV drug superior to lamivudi- ne:experience from clinical trials in China[ J ]. J Antimicrob Che- mother,2007,60:201 - 205. 被引量：1
7van Bommel F,de Man RA, Stein K, et al. A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBVmonoinfected patients with prior nucleos(t) ide analog experi- ence [ J ]. J Hepatol,2008,48 : S32. 被引量：1
8Keeffe EB,Zeuzem, Koff RS, et al. Report of an international work- shop : roadmap for management of patients receiving oral therapy for chronic hepatitis B [ J ]. Clin Gastroenterol Hepatol,2007 ,5 :890 - 897. 被引量：1
10Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [ J ]. JAMA,2006 ,295 :65 - 73. 被引量：1
